ChemoMetec A/S (LON:0DZ0)

Market Cap	1.53B
Revenue (ttm)	56.95M
Net Income (ttm)	21.42M
Shares Out	n/a
EPS (ttm)	1.23
PE Ratio	71.25
Forward PE	56.36
Dividend	0.82 (0.12%)
Ex-Dividend Date	Oct 10, 2025

Volume	664
Average Volume	1,761
Open	713.00
Previous Close	691.67
Day's Range	696.50 - 727.50
52-Week Range	378.00 - 727.50
Beta	n/a
RSI	80.21
Earnings Date	Feb 4, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 170
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0DZ0

Financial Performance

In 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK